PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Gene signature based on degradome-related genes can predict distal metastasis in cervical cancer patients.

Abstract Cervical cancer is one of the leading causes of death in women worldwide, which mainly affects developing countries. The patients who suffer a recurrence and/or progression disease have a higher risk of developing distal metastases. Proteases comprising the degradome given its ability to promote cell growth, migration, and invasion of tissues play an important role during tumor development and progression. In this study, we used high-density microarrays and quantitative reverse transcriptase polymerase chain reaction to evaluate the degradome profile and their inhibitors in 112 samples of patients diagnosed with locally advanced cervical cancer. Clinical follow-up was done during a period of 3 years. Using a correlation analysis between the response to treatment and the development of metastasis, we established a molecular signature comprising eight degradome-related genes (FAM111B, FAM111A, CFB, PSMB8, PSMB9, CASP7, PRSS16, and CD74) with the ability to discriminate patients at risk of distal metastases. In conclusion, present results show that molecular signature obtained from degradome genes can predict the possibility of metastasis in patients with locally advanced cervical cancer.
PMID
Related Publications

Fyn-related kinase expression predicts favorable prognosis in patients with cervical cancer and suppresses malignant progression by regulating migration and invasion.

Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.

The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer.

Long non-coding RNA HOTAIR is associated with human cervical cancer progression.

Clinical implication of voltage-dependent anion channel 1 in uterine cervical cancer and its action on cervical cancer cells.

Authors

Mayor MeshTerms

Proteolysis

Keywords

Degradome

cervical cancer

inhibitor proteases

locally advanced cervical cancer

metastasis

molecular markers

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28639897
OWN - NLM
STAT- MEDLINE
DA  - 20170622
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Gene signature based on degradome-related genes can predict distal metastasis in 
      cervical cancer patients.
PG  - 1010428317711895
LID - 10.1177/1010428317711895 [doi]
AB  - Cervical cancer is one of the leading causes of death in women worldwide, which
      mainly affects developing countries. The patients who suffer a recurrence and/or 
      progression disease have a higher risk of developing distal metastases. Proteases
      comprising the degradome given its ability to promote cell growth, migration, and
      invasion of tissues play an important role during tumor development and
      progression. In this study, we used high-density microarrays and quantitative
      reverse transcriptase polymerase chain reaction to evaluate the degradome profile
      and their inhibitors in 112 samples of patients diagnosed with locally advanced
      cervical cancer. Clinical follow-up was done during a period of 3 years. Using a 
      correlation analysis between the response to treatment and the development of
      metastasis, we established a molecular signature comprising eight
      degradome-related genes (FAM111B, FAM111A, CFB, PSMB8, PSMB9, CASP7, PRSS16, and 
      CD74) with the ability to discriminate patients at risk of distal metastases. In 
      conclusion, present results show that molecular signature obtained from degradome
      genes can predict the possibility of metastasis in patients with locally advanced
      cervical cancer.
FAU - Fernandez-Retana, Jorge
AU  - Fernandez-Retana J
AD  - 1 FES Iztacala, UBIMED, UNAM, Tlalnepantla, Mexico.
FAU - Zamudio-Meza, Horacio
AU  - Zamudio-Meza H
AD  - 2 Genomics Laboratory, National Cancer Institute, Mexico City, Mexico.
FAU - Rodriguez-Morales, Miguel
AU  - Rodriguez-Morales M
AD  - 2 Genomics Laboratory, National Cancer Institute, Mexico City, Mexico.
FAU - Pedroza-Torres, Abraham
AU  - Pedroza-Torres A
AD  - 2 Genomics Laboratory, National Cancer Institute, Mexico City, Mexico.
FAU - Isla-Ortiz, David
AU  - Isla-Ortiz D
AD  - 3 Unit of Cancer Biomedics Research, National Cancer Institute, Mexico City,
      Mexico.
FAU - Herrera, Luis
AU  - Herrera L
AD  - 3 Unit of Cancer Biomedics Research, National Cancer Institute, Mexico City,
      Mexico.
FAU - Jacobo-Herrera, Nadia
AU  - Jacobo-Herrera N
AD  - 4 Biochemistry Unit, National Nutrition Institute of Mexico "Salvador Zubiran,"
      Mexico City, Mexico.
FAU - Peralta-Zaragoza, Oscar
AU  - Peralta-Zaragoza O
AD  - 5 Direction of Chronic Infections and Cancer, Research Center for Infectious
      Diseases, National Institute of Public Health, Morelos, Mexico.
FAU - Lopez-Camarillo, Cesar
AU  - Lopez-Camarillo C
AD  - 6 Center for Genomic Sciences, National Autonomous University of Mexico, Mexico
      City, Mexico.
FAU - Morales-Gonzalez, Fermin
AU  - Morales-Gonzalez F
AD  - 7 Cancer Institute of Jalisco, Guadalajara, Mexico.
FAU - Cantu de Leon, David
AU  - Cantu de Leon D
AD  - 2 Genomics Laboratory, National Cancer Institute, Mexico City, Mexico.
FAU - Perez-Plasencia, Carlos
AU  - Perez-Plasencia C
AD  - 1 FES Iztacala, UBIMED, UNAM, Tlalnepantla, Mexico.
AD  - 2 Genomics Laboratory, National Cancer Institute, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Invasiveness/*genetics
MH  - Neoplasm Proteins/genetics
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - *Proteolysis
MH  - Uterine Cervical Neoplasms/*genetics/pathology
OTO - NOTNLM
OT  - Degradome
OT  - cervical cancer
OT  - inhibitor proteases
OT  - locally advanced cervical cancer
OT  - metastasis
OT  - molecular markers
EDAT- 2017/06/24 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/23 06:00
AID - 10.1177/1010428317711895 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317711895. doi: 10.1177/1010428317711895.